ChemoCentryx Inc (ChemoCentryx) is a bio pharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases and inflammatory disorders. The company's pipeline product includes Avacopan, CCX559,CCX587 and CCX507. Its Avacopan a lead candidate is an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. ChemoCentryx also provide preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.
Headquarters
United States of America
Address
835 Industrial Road, Suite 600, San Carlos, California, 94070
Website
www.chemocentryx.com
Telephone
1 650 2102900
No of Employees
178
Industry
Pharmaceuticals and Healthcare
Revenue (2021)
$32.2M
ChemoCentryx Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline | Clinical Development | Tavneos |
| Tavneos (Avacopan) | ||
| CCX559 / PD-1 / PD-L1 (Immuno-Oncology) | ||
| XYZ | ||
| XYZ | ||
| XYZ |
Competitor Comparison
| Key Parameters | ChemoCentryx Inc | Enzo Biochem Inc | Aceragen Inc | MediciNova Inc | Assertio Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Carlos | Farmingdale | Durham | La Jolla | Lake Forest |
| State/Province | California | New York | North Carolina | California | Illinois |
| No. of Employees | 178 | 179 | 26 | 13 | - |
| Entity Type | Private | Public | Private | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas J. Schall | Chief Executive Officer; President; Chairman | Executive Board | 2012 | 62 |
| Rita Jain | Director; Senior Vice President; Chief Medical Officer | Executive Board | 2019 | 59 |
| Tausif Butt | Chief Operating Officer; Executive Vice President | Senior Management | 2021 | 56 |
| Markus J. Cappel | Chief Business Officer and Treasurer | Senior Management | 2007 | 61 |
| Susan M. Kanaya | Executive Vice President; Chief Financial and Administrative Officer; Secretary | Senior Management | 2021 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward